311 related articles for article (PubMed ID: 16045774)
41. Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer - a retrospective analysis.
Piringer G; Ponholzer F; Thaler J; Bachleitner-Hofmann T; Rumpold H; de Vries A; Weiss L; Greil R; Gnant M; Öfner D
Front Oncol; 2024; 14():1374592. PubMed ID: 38817890
[TBL] [Abstract][Full Text] [Related]
42. Can the Pathological Response in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Treatment Be Predicted by the CEA/Albumin and CRP/Albumin Ratios?
Bayram E; Kidi MM; Camadan YA; Biter S; Yaslikaya S; Toyran T; Mete B; Kara IO; Sahin B
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792528
[No Abstract] [Full Text] [Related]
43. The relationship between gastric microbiome features and responses to neoadjuvant chemotherapy in gastric cancer.
Zhang P; Xu J; Zhou Y
Front Microbiol; 2024; 15():1357261. PubMed ID: 38694796
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) and platelet-neutrophil (PN) index in locally advanced rectal cancer patients: a retrospective cohort study.
Morais M; Fonseca T; Machado-Neves R; Honavar M; Coelho AR; Lopes J; Guerreiro E; Carneiro S
Ann Med Surg (Lond); 2024 May; 86(5):2474-2480. PubMed ID: 38694305
[TBL] [Abstract][Full Text] [Related]
45. Texture analysis of apparent diffusion coefficient maps: can it identify nonresponse to neoadjuvant chemotherapy for additional radiation therapy in rectal cancer patients?
Wu Q; Yi Y; Lai B; Li J; Lian Y; Chen J; Wu Y; Wang X; Cao W
Gastroenterol Rep (Oxf); 2024; 12():goae035. PubMed ID: 38651169
[TBL] [Abstract][Full Text] [Related]
46. Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes.
Soomro MY; Khan SR; Muhammad H; Ahmad S; Zehra N; Ali I; Samar MR; Hameed A; Moosajee M; Rashid YA
BMC Cancer; 2024 Apr; 24(1):479. PubMed ID: 38627736
[TBL] [Abstract][Full Text] [Related]
47. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Predicting Complete Pathological Response in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy.
Karaca M; Salim E; Alemdar MS; Deniz Karaca Ö; Arıcı MÖ
Med Sci Monit; 2024 Mar; 30():e943750. PubMed ID: 38544312
[TBL] [Abstract][Full Text] [Related]
48. Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management.
Niemann B; Moise J; Sestito M; Malla M; Train K; Murken D; Mayers K; Groves E; Garland-Kledzik M
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541909
[No Abstract] [Full Text] [Related]
49. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
Kelly RJ; Landon BV; Zaidi AH; Singh D; Canzoniero JV; Balan A; Hales RK; Voong KR; Battafarano RJ; Jobe BA; Yang SC; Broderick S; Ha J; Marrone KA; Pereira G; Rao N; Borole A; Karaindrou K; Belcaid Z; White JR; Ke S; Amjad AI; Weksler B; Shin EJ; Thompson E; Smith KN; Pardoll DM; Hu C; Feliciano JL; Anagnostou V; Lam VK
Nat Med; 2024 Apr; 30(4):1023-1034. PubMed ID: 38504015
[TBL] [Abstract][Full Text] [Related]
50. Predictive effect of the systemic inflammation response index (SIRI) on the efficacy and prognosis of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Ding Y; Liu Z; Li J; Niu W; Li C; Yu B
BMC Surg; 2024 Mar; 24(1):89. PubMed ID: 38481180
[TBL] [Abstract][Full Text] [Related]
51. Computed tomography-based radiomics nomogram for predicting therapeutic response to neoadjuvant chemotherapy in locally advanced gastric cancer : A scale for treatment predicting.
Chen W; Zhang W; Chen X; Dong W; Cai Y; Cheng J; Jin J
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38467894
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China.
Xu J; Hong Z; Cai Y; Chen Z; Lin J; Yuan X; Chen S; Xie J; Kang M; Ke S
Front Oncol; 2024; 14():1279733. PubMed ID: 38463231
[TBL] [Abstract][Full Text] [Related]
53. Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges.
Szczepanski JM; Rudolf MA; Shi J
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398185
[TBL] [Abstract][Full Text] [Related]
54. DeepRisk network: an AI-based tool for digital pathology signature and treatment responsiveness of gastric cancer using whole-slide images.
Tian M; Yao Z; Zhou Y; Gan Q; Wang L; Lu H; Wang S; Zhou P; Dai Z; Zhang S; Sun Y; Tang Z; Yu J; Wang X
J Transl Med; 2024 Feb; 22(1):182. PubMed ID: 38373959
[TBL] [Abstract][Full Text] [Related]
55. Development and validation of a nomogram to predict pathological complete response in patients with locally advanced gastric adenocarcinoma treated with neoadjuvant chemotherapy in combination with PD-1 antibodies.
Li L; Chen G; Chen EY; Strickland MR; Zhao W; Zhang J; Li Z
J Gastrointest Oncol; 2023 Dec; 14(6):2373-2383. PubMed ID: 38196541
[TBL] [Abstract][Full Text] [Related]
56. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
Han D; Han Y; Guo W; Wei W; Yang S; Xiang J; Che J; Zhu L; Hang J; van den Ende T; van Laarhoven HWM; Li B; Ye Y; Li H
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38016720
[TBL] [Abstract][Full Text] [Related]
57. Pattern of Residual Submucosal Involvement after Neoadjuvant Therapy for Rectal Cancer: A Rationale for the Utility of Endoscopic Submucosal Resection.
Elazzamy H; Bhatt M; Mazzara P; Barawi M; Zeni A; Aref A
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893525
[No Abstract] [Full Text] [Related]
58. Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival.
Chen X; Zhang Y; Zhou X; Wang M; Na F; Zhou L; Xu Y; Zou B; Xue J; Liu Y; Gong Y
Front Oncol; 2023; 13():1274924. PubMed ID: 37886166
[TBL] [Abstract][Full Text] [Related]
59. Cytoreduction and Hyperthermic Intraperitoneal Paclitaxel and Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Buckarma E; Thiels CA; Jin Z; Grotz TE
Ann Surg Oncol; 2024 Jan; 31(1):622-629. PubMed ID: 37880514
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial.
Grassi E; Zingaretti C; Petracci E; Corbelli J; Papiani G; Banchelli I; Valli I; Frassineti GL; Passardi A; Di Bartolomeo M; Pietrantonio F; Gelsomino F; Carandina I; Banzi M; Martella L; Bonetti AV; Boccaccino A; Molinari C; Marisi G; Ugolini G; Nanni O; Tamberi S
ESMO Open; 2023 Oct; 8(5):101824. PubMed ID: 37774508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
